Q1 Revenue Reaches $51.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Reports Q1 revenue $51.5M…
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZEPP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZEPP
Wall Street analysts forecast ZEPP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.200
Low
64.37
Averages
64.37
High
64.37
Current: 5.200
Low
64.37
Averages
64.37
High
64.37
No data
About ZEPP
Zepp Health Corp, formerly Huami Corp, is a Netherlands-based company primarily engaged in the consumer electronics and digital health technology industry. The Company focuses on developing smart wearable devices and digital health management platforms. Their key product is the Zepp Digital Health Management Platform, which is a cloud-based system integrating smart devices, biometric sensors, Artificial Intelligence (AI) chips, and data algorithms. It aims to provide users with 24/7 actionable insights to support health, fitness, and wellness management. The platform powers a range of products including smartwatches, fitness bands, smart rings, and hearables under the Amazfit and Zepp brand names. Additionally, the Company offers AI-driven services such as Zepp Aura for sound-based wellness and Zepp Clarity for hearing health. The Company has two reportable segments the Xiaomi wearable products segment and Self-branded products and others segment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazfit Launches Helio Strap Pro Smart Training System
- Multi-Sensor System: The Helio Strap Pro combines upper-arm heart rate monitoring with a waist-mounted motion sensor to provide a comprehensive analysis of performance, enabling HYROX and hybrid athletes to better understand their body's response under fatigue, thereby enhancing training effectiveness.
- Integration of Training and Recovery: This system not only supports real-time monitoring of training data but also integrates workouts, recovery, and daily habits into a continuous view of progress through the Zepp App, helping athletes optimize their training plans and recovery strategies.
- Compatibility and Connectivity: Helio Strap Pro supports Bluetooth connectivity with various Amazfit smartwatches and third-party devices, allowing real-time sharing of heart rate data, which enhances athletes' flexibility and adaptability in different training environments, thus improving the overall training experience.
- Market Positioning and Pricing: Scheduled for release at the end of June 2026, priced at $199.99, Helio Strap Pro aims to attract athletes interested in hybrid training through its innovative monitoring features, further solidifying Amazfit's leadership position in the smart wearable market.
See More
Zepp Health (ZEPP) Q1 2026 Earnings Transcript
See More
Zepp Health Reports Q1 Loss Reduction Amid Revenue Growth
- Financial Performance: Zepp Health reported a net loss of $19.64 million in Q1 2026, translating to a loss of $0.08 per share, which is an improvement from the $19.74 million loss in 2025, indicating better gross profit due to higher revenues.
- Revenue Growth: The company achieved revenues of $51.55 million in the first quarter, a 33.5% increase from $38.54 million a year ago, reflecting significant progress in market demand despite ongoing losses.
- Product Launches: In Q1, Zepp introduced several new products, including the Amazfit Balance 3 and Amazfit Cheetah 2 Ultra, which are designed to help users monitor health parameters during physical activities, thereby enhancing its competitive position in the wearable tech market.
- Future Outlook: The company estimates Q2 revenues to range between $63 million and $68 million, representing a 6% to 14% increase from $59.4 million reported in Q2 2025, indicating an optimistic outlook for future performance despite a 28% drop in stock price post-announcement.
See More
Zepp Health Reports Q1 Revenue Growth of 33.8%
- Significant Revenue Growth: Zepp Health reported Q1 revenue of $51.5 million, a 33.8% year-over-year increase, showcasing strong market performance in a traditionally slow quarter, which is expected to further enhance the brand's share in the smart wearable market.
- Slight Margin Improvement: The gross margin stood at 37.7%, up 0.4% year-over-year, despite pressures from higher memory component costs and unfavorable foreign exchange fluctuations, indicating the company's ability to maintain some cost control.
- Narrowed Operating Loss: Operating loss decreased from $17.2 million in the previous year to $6.3 million, reflecting progress in cost management and operational efficiency, with potential for future profitability growth.
- Optimistic Future Outlook: The company expects Q2 revenue to range between $63 million and $68 million, representing a year-over-year growth of approximately 6% to 14%, driven by new product launches and strong market demand, further solidifying its market position.
See More
Zepp Health Q1 Results Show Revenue Growth Amid Losses
- Revenue Growth: Zepp Health reported a 33.8% year-over-year revenue increase to $51.5 million in Q1, aligning with guidance and driven by new product launches, although overall market sentiment was weighed down by ongoing losses.
- Margin Fluctuations: Gross margin edged up to 37.7% from 37.3% a year earlier, but declined sequentially due to lower-margin product refreshes, higher component costs, and currency headwinds, indicating challenges in cost management.
- Net Loss Report: The company reported a net loss of $19.6 million, roughly unchanged from the previous year, while the adjusted operating loss narrowed to $16.3 million, suggesting some progress in operational efficiency improvements.
- Future Outlook: Zepp expects second-quarter revenue between $63 million and $68 million, implying a year-over-year growth of 6% to 14%, reflecting the company's optimistic outlook on market demand.
See More
Zepp Health Reports Q1 2026 Earnings Results
- Earnings Highlights: Zepp Health reported a Q1 2026 non-GAAP EPS of -$1.13, yet achieved revenues of $51.55 million, reflecting a robust year-over-year growth of 33.8%, indicating strong market demand.
- Gross Margin Improvement: The gross margin for Q1 stood at 37.7%, an increase of 0.4 percentage points compared to Q1 2025, showcasing effective cost management and operational efficiency that enhance profitability.
- Future Outlook: Management anticipates Q2 2026 net revenues between $63.0 million and $68.0 million, representing a year-over-year growth of approximately 6% to 14%, which underscores confidence in sustained market demand.
- Risk Assessment: Despite significant revenue growth, analysts have downgraded Zepp Health's rating, citing concerns over compressing gross margins, which may pose challenges to future profitability and investor sentiment.
See More
Amazfit Launches Helio Strap Pro Smart Training System
- Multi-Sensor System: The Helio Strap Pro combines upper-arm heart rate monitoring with a waist-mounted motion sensor to provide a comprehensive analysis of performance, enabling HYROX and hybrid athletes to better understand their body's response under fatigue, thereby enhancing training effectiveness.
- Integration of Training and Recovery: This system not only supports real-time monitoring of training data but also integrates workouts, recovery, and daily habits into a continuous view of progress through the Zepp App, helping athletes optimize their training plans and recovery strategies.
- Compatibility and Connectivity: Helio Strap Pro supports Bluetooth connectivity with various Amazfit smartwatches and third-party devices, allowing real-time sharing of heart rate data, which enhances athletes' flexibility and adaptability in different training environments, thus improving the overall training experience.
- Market Positioning and Pricing: Scheduled for release at the end of June 2026, priced at $199.99, Helio Strap Pro aims to attract athletes interested in hybrid training through its innovative monitoring features, further solidifying Amazfit's leadership position in the smart wearable market.
See More
Zepp Health (ZEPP) Q1 2026 Earnings Transcript
See More
Zepp Health Reports Q1 Loss Reduction Amid Revenue Growth
- Financial Performance: Zepp Health reported a net loss of $19.64 million in Q1 2026, translating to a loss of $0.08 per share, which is an improvement from the $19.74 million loss in 2025, indicating better gross profit due to higher revenues.
- Revenue Growth: The company achieved revenues of $51.55 million in the first quarter, a 33.5% increase from $38.54 million a year ago, reflecting significant progress in market demand despite ongoing losses.
- Product Launches: In Q1, Zepp introduced several new products, including the Amazfit Balance 3 and Amazfit Cheetah 2 Ultra, which are designed to help users monitor health parameters during physical activities, thereby enhancing its competitive position in the wearable tech market.
- Future Outlook: The company estimates Q2 revenues to range between $63 million and $68 million, representing a 6% to 14% increase from $59.4 million reported in Q2 2025, indicating an optimistic outlook for future performance despite a 28% drop in stock price post-announcement.
See More
Zepp Health Reports Q1 Revenue Growth of 33.8%
- Significant Revenue Growth: Zepp Health reported Q1 revenue of $51.5 million, a 33.8% year-over-year increase, showcasing strong market performance in a traditionally slow quarter, which is expected to further enhance the brand's share in the smart wearable market.
- Slight Margin Improvement: The gross margin stood at 37.7%, up 0.4% year-over-year, despite pressures from higher memory component costs and unfavorable foreign exchange fluctuations, indicating the company's ability to maintain some cost control.
- Narrowed Operating Loss: Operating loss decreased from $17.2 million in the previous year to $6.3 million, reflecting progress in cost management and operational efficiency, with potential for future profitability growth.
- Optimistic Future Outlook: The company expects Q2 revenue to range between $63 million and $68 million, representing a year-over-year growth of approximately 6% to 14%, driven by new product launches and strong market demand, further solidifying its market position.
See More
Zepp Health Q1 Results Show Revenue Growth Amid Losses
- Revenue Growth: Zepp Health reported a 33.8% year-over-year revenue increase to $51.5 million in Q1, aligning with guidance and driven by new product launches, although overall market sentiment was weighed down by ongoing losses.
- Margin Fluctuations: Gross margin edged up to 37.7% from 37.3% a year earlier, but declined sequentially due to lower-margin product refreshes, higher component costs, and currency headwinds, indicating challenges in cost management.
- Net Loss Report: The company reported a net loss of $19.6 million, roughly unchanged from the previous year, while the adjusted operating loss narrowed to $16.3 million, suggesting some progress in operational efficiency improvements.
- Future Outlook: Zepp expects second-quarter revenue between $63 million and $68 million, implying a year-over-year growth of 6% to 14%, reflecting the company's optimistic outlook on market demand.
See More
Zepp Health Reports Q1 2026 Earnings Results
- Earnings Highlights: Zepp Health reported a Q1 2026 non-GAAP EPS of -$1.13, yet achieved revenues of $51.55 million, reflecting a robust year-over-year growth of 33.8%, indicating strong market demand.
- Gross Margin Improvement: The gross margin for Q1 stood at 37.7%, an increase of 0.4 percentage points compared to Q1 2025, showcasing effective cost management and operational efficiency that enhance profitability.
- Future Outlook: Management anticipates Q2 2026 net revenues between $63.0 million and $68.0 million, representing a year-over-year growth of approximately 6% to 14%, which underscores confidence in sustained market demand.
- Risk Assessment: Despite significant revenue growth, analysts have downgraded Zepp Health's rating, citing concerns over compressing gross margins, which may pose challenges to future profitability and investor sentiment.
See More
